REG - Arc Minerals Limited - Exercise of Warrants & Issue of Equity

ARC MineralsAnnouncement

18/07/2019 16:15

RNS Number : 0338G
Arc Minerals Limited
18 July 2019
 


18 July 2019
Arc Minerals Ltd 
('Arc' or the 'Company')
Exercise of Warrants & Issue of Equity
Arc Minerals announces that it has received notification from a warrant holder to exercise warrants over a total of 1,671,144 New Ordinary Shares of no par value in the share capital of the Company (the 'New Ordinary Shares') at a price of 2.8 pence per share. Accordingly, the Company has today issued the New Ordinary Shares to the warrant holder for an aggregate cash value of £46,792.03.
Application has been made for the New Ordinary shares to be admitted to trading on the AIM market of the London Stock Exchange ('Admission'). Admission is expected to occur on or around 24 July 2019.
Total Voting Rights
Following the issue of the Shares, the total issued share capital of the Company will consist of 710,222,695 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 710,222,695 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company.
For more information visit www.arcminerals.com.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
**ENDS**
Contacts



Arc Minerals Ltd
Nick von Schirnding (Chairman)
 


+44 (0) 20 7917 2942
 




SP Angel (Nominated Adviser & Broker)
Ewan Leggat / Soltan Tagiev
 


+44 (0) 20 3470 0470
 



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEGGUUGMUPBGAR